Literature DB >> 1284591

Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer.

S Vijayakumar1, T Karrison, R R Weichselbaum, S Chan, S F Quadri, A M Awan.   

Abstract

Prostate cancer is a significant health problem for blacks. The incidence and mortality rates are higher in blacks than in whites; blacks often present with a higher stage. Prostate-specific antigen (PSA) is a very useful serum marker in prostate cancer. We analyzed data from a cohort of 161 patients to determine whether there were any racial differences in PSA levels prior to treatment in local-regional prostate cancer. The immunoradiometric method was used to determine the PSA values. The mean PSA levels were significantly higher in blacks than in whites (P = 0.022), and the difference remained significant in multivariate analysis after adjusting for stage and grade (P = 0.020). However, when analyzed further, the difference was statistically significant in one hospital (P = 0.001) and not in another (P = 0.493). Thus, our results are not unequivocal, but our data do suggest that racial differences in PSA levels not accounted for by tumor stage or grade may exist. Assuming that the data truly reflect a racial difference, the cause(s) of this difference remains to be determined. It may exist because, within each clinical stage, blacks are presenting with a higher tumor cell burden, or it may be indicative of more aggressive biological behavior. The possibility that racial differences are due to socioeconomic factors was considered by estimating median income level from zip code of residence; although a correlation between socioeconomic status and PSA level was found, racial differences remained borderline significant (P = 0.055) after adjusting for income level (in addition to stage and grade).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1284591

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  8 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

Review 2.  Molecular genetics of prostate cancer: clinical applications.

Authors:  R A Morton; W B Isaacs
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

3.  Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.

Authors:  R C Bergan; R G Walls; W D Figg; N A Dawson; D Headlee; A Tompkins; S M Steinberg; E Reed
Journal:  J Natl Med Assoc       Date:  1997-09       Impact factor: 1.798

4.  Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients.

Authors:  S O Asbell; K C Raimane; A T Montesano; K L Zeitzer; M D Asbell; S Vijayakumar
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

5.  Prostate cancer: epidemiology and screening.

Authors:  M K Brawer; E D Crawford; J Fowler; M S Lucia; F H Schröeder
Journal:  Rev Urol       Date:  2000

6.  Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.

Authors:  Veda N Giri; Brian Egleston; Karen Ruth; Robert G Uzzo; David Y T Chen; Mark Buyyounouski; Susan Raysor; Stanley Hooker; Jada Benn Torres; Teniel Ramike; Kathleen Mastalski; Taylor Y Kim; Rick Kittles
Journal:  Cancer Prev Res (Phila)       Date:  2009-02-24

Review 7.  Do African-American men need separate prostate cancer screening guidelines?

Authors:  Divya Shenoy; Satyaseelan Packianathan; Allen M Chen; Srinivasan Vijayakumar
Journal:  BMC Urol       Date:  2016-05-10       Impact factor: 2.264

Review 8.  Screening for prostate cancer in African Americans.

Authors:  J W Moul
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.